So a SPL board member is going to financially benefit from this ‘deal’?
This vulture capitalist no-licence fee and no-milestone payment research agreement gets smellier by the minute.
As I pondered on Hotcopper prior to the webinar: Is anyone employed by Starpharma or an associate of the company going to be drawing a salary or providing consulting services to Petalion?
And what do shareholders get out of this in 4-8 years if the pre-clinical research or subsequent potential early stage clinical trial is not successful?
Nothing. Zero. Shareholders get nothing. This stinks!
